DENVER, March 10, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that it has entered into an arrangement agreement dated March 10, 2020 (the “Arrangement Agreement”) with a newly-incorporated wholly-owned subsidiary, (“Spinco”). Under the Arrangement Agreement, Mydecine will transfer its [ U.S.


Previous articleMindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)
Next articleGroup Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier